Perioperative Use of Amniotic Allografts: Surgical Applications

Amniotic allografts are increasingly used as a perioperative biologic adjunct to support healing, modulate inflammation, and reduce scarring in a range of surgical settings. Unlike many synthetic dressings, amniotic membrane contains extracellular matrix components, growth factors, and cytokines that interact directly with the wound bed. For surgical teams evaluating advanced wound biologics, the relevant question is not whether amniotic membrane works in general, but where the evidence supports its use perioperatively and how it fits into existing protocols.

Clinical Evidence Across Surgical Indications

Amniotic allografts have been studied across multiple surgical and wound applications. The evidence base is heterogeneous, but several well-defined indications are supported by published literature.

Hand and Upper Extremity Surgery

Amniotic membrane products are regulated by the FDA as human cells, tissues, and cellular- and tissue-based products. Reported clinical applications include nerve repair, tendon injury, joint and cartilage damage, and wound management. McClendon et al. note that although in vitro evidence describes amnion-derived cells as containing mediators that promote cellular proliferation, differentiation, and epithelialization while inhibiting fibrosis, immune rejection, inflammation, and bacterial invasion, clinical literature specific to hand and wrist pathology remains limited. Further investigation is needed to determine their therapeutic value in the upper extremity.

Ocular Surface and Limbal Stem Cell Deficiency

Amniotic membrane transplantation has an established role in ocular surface reconstruction, including chemical and thermal burns, Stevens-Johnson syndrome, and limbal stem cell deficiency (LSCD). The 2020 Global Consensus on the Management of LSCD identifies amniotic membrane transplantation as a core surgical option, alongside conjunctival epitheliectomy, limbal stem cell transplantation, and keratoprosthesis. For unilateral or bilateral disease, the consensus recommends optimizing the ocular surface first (treating inflammation, dry eye, and eyelid disease) before selecting a surgical strategy that may include amniotic membrane.

Burns and Genital Reconstruction

A retrospective comparison of dehydrated human amniotic/chorionic membrane (DHACM) versus cryopreserved allografts for partial-thickness genital burns found that all DHACM-treated patients healed by two weeks postoperatively, compared with 76% in the cryopreserved group. The cryopreserved group also required a higher rate of reapplication (28% versus 0%). This supports DHACM as a viable biologic dressing for acute burns in a sensitive anatomic region, though the study was retrospective and limited in sample size.

Perioperative Protocol Considerations

Amniotic allografts are not a substitute for standard of care. They are most useful when used as an adjunct to debridement, hemostasis, infection control, and offloading or compression. The following practical points should guide perioperative use.

• Patient selection: Best candidates are those with compromised healing due to inflammation, poor vascularity, or large wound surface area. Use is generally adjunctive, not stand-alone.
• Wound bed preparation: Remove nonviable tissue, control bioburden, and ensure adequate perfusion before applying the graft.
• Application timing: Apply intraoperatively or at the first postoperative dressing change depending on the product format and indication.
• Fixation and dressing: Follow the manufacturer’s instructions for orientation, fixation, and secondary dressing. Moisture balance and offloading remain critical.
• Documentation: Record graft size, application site, and wound characteristics to support continuity of care and reimbursement review.

Product and Processing Comparison

Not all amniotic products are equivalent. Processing methods affect shelf life, storage requirements, and retention of biological activity.

McDaniel et al. showed that lyophilized amniotic membrane sterilized with supercritical carbon dioxide maintained similar biochemical properties and biocompatibility compared with cryopreserved alternatives, suggesting that modern processing can preserve key biological properties without requiring specialized cold storage.

How Amniotic Allografts Fit in the Broader Skin Substitute Landscape

Skin substitutes are categorized by the skin layer they replace and their source material, including epidermal, dermal, and composite options, as well as xenograft, acellular allograft, cellular allograft, autograft, and synthetic substitutes. Because no single product meets all wound-healing requirements, selection should be based on clinical indication, wound depth, vascular status, and patient comorbidities.

Amniotic and chorionic allografts are one option among several biologic dressings. Their proposed advantages include low immunogenicity, anti-inflammatory properties, and promotion of epithelialization. However, they are not appropriate for every wound type. Venous leg ulcers, for example, require compression therapy and endovenous ablation when axial reflux is present; biologics may be considered adjunctively when standard care fails.

Key Takeaways

• Amniotic allografts have established perioperative roles in ocular surface reconstruction, acute burns, and wound management, with emerging use in hand and upper-extremity surgery.
• Processing matters: lyophilized products can retain biological activity while simplifying storage and logistics.
• Patient selection, wound-bed preparation, and adherence to standard-of-care principles determine outcomes more than graft choice alone.
• Clinicians should match the product to the indication and document application details clearly.